Chief Medical Officer Directorate Pharmacy and Medicines Division



Medicine Supply Alert Notice

15 November 2019

PROVERA[®] (MEDROXYPROGESTERONE ACETATE) 100mg AND 200mg TABLETS - Update

Priority: Level 2¹ Valid until: Ongoing

Issue

1. Pfizer, sole supplier of Provera® tablets, have advised that:

- Resupply of Provera[®] 100mg tablets is delayed until 13 December 2019;
- Provera[®] 200mg tablets are now out of stock until 20 December 2019; and
- Provera[®] 400mg tablets are available but cannot support an increase in demand.
- 2. Unlicensed imports of medroxyprogesterone 100mg tablets remain available.

Advice and Actions

3. For patients without sufficient supplies of Provera[®] tablets to last until the resolution date, prescribers may consider prescribing an unlicensed import (see additional information below).

4. If unlicensed imports are not considered suitable then patients should be referred to secondary care specialists for further management.

Additional Information

5. The following specialist importers have currently confirmed availability of unlicensed medroxyprogesterone 100mg tablets:

- Target Healthcare Ltd;
- Mawdsleys.

6. Any decision to prescribe an unlicensed medicine must consider the relevant health board guidance and local governance procedures. Please see the links below for further information:

- Prescribing unlicensed medicines, General Medical Council (GMC),
- <u>The supply of unlicensed medicinal products</u>, Medicines and Healthcare products Regulatory Agency (MHRA)
- <u>Professional Guidance for the Procurement and Supply of Specials</u>, Royal Pharmaceutical Society (RPS)

Enquiries

1

7. Any enquiries should be directed to PharmacyTeam@gov.scot

https://nhsnss.org/media/3874/medicine-supply-alert-notices-definitions-of-classifications-21-october-2019.docx